There is one question that the vast majority of Indian small-cap investors never ask when analysing a company. They check the P/E ratio. They study the promoter holding. They look at the ROCE and the debt-to-equity. But they almost never ask: what percentage of this company’s revenue comes from its single largest customer?
That one unanswered question has destroyed more small-cap portfolios than any market crash, interest rate hike, or geopolitical shock. It is called Customer Concentration Risk — and it is the hidden valuation killer that Wall Street analysts obsess over while Dalal Street retail investors barely know it exists.
In this post, we will dissect this concept completely, understand why it is so dangerous for Indian small-cap investors, learn how to measure and find it, and see why quality businesses like Titan Biotech have deliberately built their revenue structure to eliminate this exact risk.
What is Customer Concentration Risk?
Customer concentration risk is the danger that arises when a business depends on a small number of customers — or even a single customer — for a disproportionately large share of its revenue. If that customer delays payments, cancels orders, renegotiates terms, or simply finds a cheaper supplier, the company’s financials can collapse almost overnight.
A commonly used threshold is this: if any single customer contributes more than 10% of total revenue, that is a concentration risk worth examining. If the top 5 customers together account for more than 60% of revenue, the business is structurally fragile regardless of how strong its financial ratios appear on a screener.
Think of it as a table with very few legs. It might look sturdy when everything is balanced — but remove even one leg and the entire structure collapses.
Why Indian Small-Caps Are Especially Vulnerable
In India’s small-cap and mid-cap universe, customer concentration is a far more prevalent problem than most investors realise. Many small Indian manufacturers start their journey by winning one or two anchor clients — often large government entities, PSUs, or export buyers — who give them volume but come with an implicit threat: lose this one account and your factory runs at 30% capacity overnight.
Smaller companies often lack the sales infrastructure or brand equity to diversify their client base quickly. They are operationally excellent but commercially fragile. Indian promoters frequently disclose customer concentration only in the annual report’s “Notes to Accounts” section — buried under dense legal language that retail investors never read.
The result: an investor buys a company with a 28% operating margin and a beautiful 5-year revenue CAGR of 22%, only to watch the stock crash 50% in a single quarter when its largest client shifts its sourcing to a competing vendor.
Real-World Impact: What Customer Concentration Does to a Stock
Consider the case pattern that has played out repeatedly in Indian small-cap history. A textile ancillary manufacturer with a clean balance sheet and high margins reports stellar quarterly numbers for 12 consecutive quarters. Retail investors pile in. The stock trades at 35x earnings. Then, in a single disclosure, the company reveals that its largest client — an international retail chain — has decided to nearshore its sourcing. Revenue from that client was 38% of total. The stock falls 65% in three months.
Similarly, an IT services company in the mid-cap space once had 47% of its revenue coming from one US financial services firm. When that firm was acquired and the acquirer renegotiated all vendor contracts at steep discounts, the mid-cap’s earnings collapsed by 40% in a single year.
The lesson: the concentration risk was always in the annual report. Most investors simply never looked.
How to Measure Customer Concentration: Practical Tools
1. Significant Customer Disclosure: SEBI requires Indian listed companies to disclose customers contributing more than 10% of revenue. Found in Notes to Financial Statements or MD&A. Read the last three annual reports and compare year-over-year.
2. Segment Revenue Breakdown: If a company has a single segment serving one or two industries, any sectoral downturn automatically creates concentration risk. Geographic concentration (all revenue from one country) is equally dangerous.
3. HHI for Revenue: Apply the Herfindahl-Hirschman Index to customer revenue breakdowns. A score above 2,500 indicates dangerously high concentration.
4. Debtors Concentration: If one party accounts for 40%+ of trade receivables, that is a direct proxy for customer concentration. High debtor concentration paired with rising DDO is a red flag.
5. Management AGM Transcripts: Note when a company says “our relationship with X continues to be strong” in every call — it is often code for “X is our single largest revenue source.”
Titan Biotech’s 100-Country Diversification Fortress
Titan Biotech Ltd (BSE: 524717) teaches a masterclass in how quality businesses are built. As of FY2025, Titan Biotech exports its products to more than 100 countries. This extraordinary geographic diversification means that no single country — let alone a single customer — can meaningfully disrupt the company’s revenue stream.
Titan Biotech earns approximately 34.5% of its total revenue from exports. The remaining domestic revenue is spread across multiple industries — pharmaceuticals, food, dairy, diagnostics, cosmetics, and research — further reducing single-customer dependency.
With a market cap of ₹1,694 Cr, stock price of ₹410, ROCE of 16.9%, promoter holding of 55.78%, debt-to-equity of just 0.02x, and a profit CAGR of 26% over 5 years, Titan Biotech demonstrates that superior diversification is not just risk management — it is a competitive moat.
A Five-Point Framework for Customer Concentration Analysis
Point 1 — The 10% Rule: Does any single customer contribute more than 10% of revenue? Flag it. If not clearly disclosed, that is a governance red flag.
Point 2 — Trend Direction: Is concentration increasing or decreasing over the last 3 years? Increasing concentration creates future vulnerability even in growing businesses.
Point 3 — Switching Cost Analysis: How easy is it for that large customer to switch to a competitor? Commoditised products with zero switching cost make concentration risk existential.
Point 4 — Customer Financial Health: A concentrated revenue source that is also financially leveraged or in a declining industry doubles the risk.
Point 5 — Management’s Diversification Plan: Is the management actively investing in new geographies and product lines? Management candour on this topic is itself a quality signal.
Build Long-Term Wealth, Not Short-Term Thrills
Understanding customer concentration risk requires deep fundamental research — reading annual reports, asking the right questions, and thinking like a business owner. SEBI data reveals that 9 out of 10 individual traders in F&O incur net losses. Quality investors who study fundamentals consistently outperform because they are buying businesses, not betting on price movements.
For our complete value investing education series: Value Investing Course by Manish Goel
SEBI Disclaimer: 9 out of 10 individual traders in the equity Futures & Options segment incurred net losses according to a SEBI study. F&O trading is essentially gambling. Focus on quality stock picking and long-term value investing instead.
Disclaimer: The author (Manish Goel) is a SEBI Registered Research Analyst (Registration No. INH100004775) and Multibagger Shares (Multibagger Securities Research & Advisory Pvt. Ltd.) is a SEBI Registered Investment Advisor (Registration No. INA100007736). This post is for educational purposes only and should not be construed as a buy/sell recommendation. Please do your own research and consult a qualified financial advisor before making investment decisions. Stock market investments are subject to market risks. Past performance is not indicative of future results.
📱 Join Our Free Telegram Channel
Get daily value investing insights, market updates, and Titan Biotech analysis — completely free.
